apilimod

Also Known As:

STA 5326; STA 5326 mesilate; STA 5326 mesylate; STA-5326; STA-5326 mesilate; STA-5326 mesylate; STA5326; apilimod bis-mesylate; apilimod bismesylate; apilimod dimesylate; apilimod mesilate; apilimod mesylate

Networked: 28 relevant articles (4 outcomes, 12 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Hydrazines: 379
  - Hydrazones: 500
    - apilimod: 28
Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Pyrimidines: 510
    - apilimod: 28
  - Oxazines: 9
    - Morpholines: 6
      - apilimod: 28

Experts

1.	Kirchhausen, Tom: 4 articles (10/2021 - 01/2020)
2.	Wada, Yumiko: 3 articles (01/2012 - 02/2007)
3.	Balistreri, Giuseppe: 2 articles (10/2021 - 08/2021)
4.	Kreutzberger, Alex J B: 2 articles (10/2021 - 08/2021)
5.	Ojha, Ravi: 2 articles (10/2021 - 08/2021)
6.	Pyle, Jesse D: 2 articles (10/2021 - 08/2021)
7.	Sanyal, Anwesha: 2 articles (10/2021 - 08/2021)
8.	Vapalahti, Olli: 2 articles (10/2021 - 08/2021)
9.	Case, James Brett: 2 articles (06/2020 - 01/2020)
10.	Chen, Rita E: 2 articles (06/2020 - 01/2020)

Related Diseases

1.	Inflammation (Inflammations) 11/01/2010 - "These results indicate that oral administration of STA-5326 is effective in suppressing inflammation in the EAU model. " 11/01/2010 - "Furthermore, oral administration of STA-5326 during the effector phase of EAU ameliorated the severity of inflammation. " 01/01/2008 - "These results indicate that oral administration of the IL-12/IL-23 inhibitor STA-5326 is effective in suppressing inflammation in the EAU model, and reduces the expansion of IL-17-producing cells. "
2.	Crohn Disease (Crohn's Disease) 07/01/2010 - "We performed a multicenter, Phase 2, randomized, double-blinded, placebo-controlled study to evaluate the efficacy of apilimod mesylate in treating 220 adult patients with moderate-to-severe CD (Crohn's Disease Activity Index [CDAI] score 220-450). " 01/01/2007 - "Patients with CD responded within 14 days of treatment with apilimod and, after 28 days, the drug significantly reduced the Crohn's disease activity index (CDAI). " 07/01/2006 - "Oral qd dosing of STA 5326 for 4 weeks was well tolerated in doses up to 70 mg qd in patients with active moderate to severe Crohn's disease. " 01/01/2013 - "Apilimod is currently undergoing investigation in a number of clinical trials for the treatment of auto-immune conditions such as Crohn's disease and Rheumatoid Arthritis. " 02/01/2007 - "STA-5326 currently is being evaluated in phase 2 clinical trials in patients with Crohn disease and rheumatoid arthritis."
3.	Rheumatoid Arthritis 01/01/2013 - "Apilimod is currently undergoing investigation in a number of clinical trials for the treatment of auto-immune conditions such as Crohn's disease and Rheumatoid Arthritis. " 02/01/2007 - "STA-5326 currently is being evaluated in phase 2 clinical trials in patients with Crohn disease and rheumatoid arthritis." 01/01/2007 - "Apilimod is currently in phase II clinical trials for rheumatoid arthritis, common variable immunodeficiency and CD. " 06/01/2012 - "To investigate the safety, tolerability, pharmacokinetics, and efficacy of apilimod mesylate, an oral interleukin-12 (IL-12)/IL-23 inhibitor, in patients with rheumatoid arthritis (RA). " 07/25/2013 - "Apilimod is a potent small molecular inhibitor of IL-12/IL-23 with an unknown target and has been evaluated in clinical trials for patients with Crohn's disease or rheumatoid arthritis. "
4.	COVID-19 12/01/2022 - "One such compound, Apilimod, is being considered as a COVID-19 therapeutic in a Phase II efficacy trial. " 12/27/2020 - "The PIKfyve inhibitor apilimod is currently undergoing clinical trials for treatment of COVID-19. " 01/01/2022 - "Apilimod is currently under clinical trial (NCT04446377) for COVID19 supporting the validity and robustness of our screening approach." 12/27/2020 - "We therefore warn that the immunosuppression observed in many COVID-19 patients might be aggravated by apilimod." 12/27/2020 - "The PIKfyve Inhibitor Apilimod: A Double-Edged Sword against COVID-19."
5.	Infections 01/01/2017 - "Here we analyzed the effects of apilimod, a PIKfyve inhibitor that was reported to be well tolerated in humans in phase 2 clinical trials, for its effects on entry and infection of EBOV and Marburg virus (MARV). " 01/01/2023 - "We also found that the virus used the late endosomal and lysosomal pathway for cell entry and that the infection could be blocked by apilimod, an inhibitor of cellular PIK5K." 01/01/2017 - "Given the drug's observed anti-filoviral activity, relatively unexplored mechanism of entry inhibition, and reported tolerability in humans, we propose that apilimod be further explored as part of a therapeutic regimen to treat filoviral infections." 01/01/2017 - "We first found that apilimod blocks infections by EBOV and MARV in Huh 7, Vero E6 and primary human macrophage cells, with notable potency in the macrophages (IC50, 10 nM). " 01/01/2017 - "The phosphatidylinositol-3-phosphate 5-kinase inhibitor apilimod blocks filoviral entry and infection."

Related Drugs and Biologics

1.	Interleukin-12 (IL 12)
2.	Interleukin-23 (Interleukin 23)
3.	Immunologic Factors (Immunomodulators)
4.	Adenosine Triphosphate (ATP)
5.	Phosphotransferases (Kinase)
6.	Proteins (Proteins, Gene)
7.	Phosphatidylinositols (Phosphatidylinositol)
8.	nafamostat
9.	Phosphates (Orthophosphate)
10.	Cathepsins

Related Therapies and Procedures

1.	Oral Administration